Immune modulation by chemotherapy or immunotherapy to enhance cancer vaccines

Cancers

Volumn 3, Issue 3, 2011, Pages 3114-3142

  Weir, Genevieve M ^a,b   Liwski, Robert S ^b   Mansour, Marc ^a  

^a Immunovaccine Inc   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Cancer; Chemotherapy; Immune modulation; Immunotherapy; Vaccine

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CANCER VACCINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; INTERLEUKIN 2; IPILIMUMAB; MDX 1106; MITOMYCIN C; MONOCLONAL ANTIBODY; MUCIN 1; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEPTIDE VACCINE; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN ANTIBODY; TEMOZOLOMIDE; TICILIMUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVANCED CANCER; BILIARY TRACT CANCER; BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; COLON CANCER; COLON CARCINOMA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; GLIOBLASTOMA; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; LEWIS CARCINOMA; LIVER CELL CARCINOMA; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MELANOMA; MELANOMA B16; MOLECULAR DYNAMICS; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NEOPLASM; NONHUMAN; OUTCOME ASSESSMENT; OVARY CANCER; PANCREAS CANCER; PATIENT COMPLIANCE; REVIEW; THYMOMA; TREATMENT DURATION; TREATMENT PLANNING; TUMOR ESCAPE;

EID: 80053280757     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers3033114     Document Type: Review

References (144)

1. Hirsch, J. An anniversary for cancer chemotherapy. JAMA 2006, 296, 1518-1520.
2. Zitvogel, L.; Apetoh, L.; Ghiringhelli, F.; Kroemer, G. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 2008, 8, 59-73.
3. Cooke, S.L.; Brenton, J.D. Evolution of platinum resistance in high-grade serous ovarian cancer. Lancet. Oncol. 2011 doi:10.1016/S1470-2045(11)70123-1.
4. Boeckmann, L.; Nickel, A.C.; Kuschal, C.; Schaefer, A.; Thoms, K.M.; Schon, M.P.; Thomale, J.; Emmert, S. Temozolomide chemoresistance heterogeneity in melanoma with different treatment regimens: DNA damage accumulation contribution. Melanoma Res. 2011, 21, 206-216.
5. Chamie, K.; Kurzrock, E.A.; Evans, C.P.; Litwin, M.S.; Koppie, T.M.; Wootton-Gorges, S.L.; Boone, J.M.; Lara, P.N., Jr.; Devere White, R.W. Secondary malignancies among nonseminomatous germ cell tumor cancer survivors. Cancer 2011, doi: 10.1002/cncr.26038.
6. Dasanu, C.A.; Alexandrescu, D.T. Risk of additional cancers in untreated and treated hairy cell leukemia patients. Expert. Opin. Pharmacother. 2010, 11, 41-50.
7. Stewart, T.J.; Smyth, M.J. Improving cancer immunotherapy by targeting tumor-induced immune suppression. Cancer Metastasis. Rev. 2011, 30, 125-140.
8. Curiel, T.J.; Coukos, G.; Zou, L.; Alvarez, X.; Cheng, P.; Mottram, P.; Evdemon-Hogan, M.; Conejo-Garcia, J.R.; Zhang, L.; Burow, M.; et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004, 10, 942-949.
9. Ostrand-Rosenberg, S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol. Immunother. 2010, 59, 1593-1600.
10. - lymphocytes is thymus and proliferation independent. Cancer Res. 2006, 66, 4488-4495.
11. Flavell, R.A.; Sanjabi, S.; Wrzesinski, S.H.; Licona-Limon, P. The polarization of immune cells in the tumour environment by TGFbeta. Nat. Rev. Immunol. 2010, 10, 554-567.
12. + regulatory T cells improves effective therapeutic vaccination against established melanoma. Cancer Res. 2010, 70, 7788-7799.
13. Teng, M.W.; Ngiow, S.F.; von Scheidt, B.; McLaughlin, N.; Sparwasser, T.; Smyth, M.J. Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth. Cancer Res. 2010, 70, 7800-7809.
14. Wilke, C.M.; Wu, K.; Zhao, E.; Wang, G.; Zou, W. Prognostic significance of regulatory T cells in tumor. Int. J. Cancer 2010, 127, 748-758.
15. Zou, W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 2006, 6, 295-307.
16. Ueha, S.; Shand, F.H.; Matsushima, K. Myeloid cell population dynamics in healthy and tumorbearing mice. Int. Immunopharmacol. 2011, 11, 783-788.
17. Rodrigues, J.C.; Gonzalez, G.C.; Zhang, L.; Ibrahim, G.; Kelly, J.J.; Gustafson, M.P.; Lin, Y.; Dietz, A.B.; Forsyth, P.A.; Yong, V.W.; et al. Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. Neuro. Oncol. 2010, 12, 351-365.
18. Bunt, S.K.; Sinha, P.; Clements, V.K.; Leips, J.; Ostrand-Rosenberg, S. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J. Immunol. 2006, 176, 284-290.
19. + immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1beta-secreting cells. J. Immunol. 2005, 175, 8200-8208.
20. Almand, B.; Clark, J.I.; Nikitina, E.; van Beynen, J.; English, N.R.; Knight, S.C.; Carbone, D.P.; Gabrilovich, D.I. Increased production of immature myeloid cells in cancer patients: A mechanism of immunosuppression in cancer. J. Immunol. 2001, 166, 678-689.
21. Almand, B.; Resser, J.R.; Lindman, B.; Nadaf, S.; Clark, J.I.; Kwon, E.D.; Carbone, D.P.; Gabrilovich, D.I. Clinical significance of defective dendritic cell differentiation in cancer. Clin. Cancer Res. 2000, 6, 1755-1766.
22. Movahedi, K.; Guilliams, M.; Van den Bossche, J.; Van den Bergh, R.; Gysemans, C.; Beschin, A.; De Baetselier, P.; Van Ginderachter, J.A. Identification of discrete tumor-induced myeloidderived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008, 111, 4233-4244.
23. Bak, S.P.; Alonso, A.; Turk, M.J.; Berwin, B. Murine ovarian cancer vascular leukocytes require arginase-1 activity for T cell suppression. Mol. Immunol. 2008, 46, 258-268.
24. Srivastava, M.K.; Sinha, P.; Clements, V.K.; Rodriguez, P.; Ostrand-Rosenberg, S. Myeloidderived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res. 2010, 70, 68-77.
25. + T cell tolerance in cancer. Nat. Med. 2007, 13, 828-835.
26. Nagaraj, S.; Schrum, A.G.; Cho, H.I.; Celis, E.; Gabrilovich, D.I. Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J. Immunol. 2010, 184, 3106-3116.
27. + T cells. J. Immunol. 2009, 183, 937-944.
28. Serafini, P.; Mgebroff, S.; Noonan, K.; Borrello, I. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res. 2008, 68, 5439-5449.
29. Pan, P.Y.; Ma, G.; Weber, K.J.; Ozao-Choy, J.; Wang, G.; Yin, B.; Divino, C.M.; Chen, S.H. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res. 2010, 70, 99-108.
30. + T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat. Med. 1999, 5, 780-787.
31. Movahedi, K.; Laoui, D.; Gysemans, C.; Baeten, M.; Stange, G.; Van den Bossche, J.; Mack, M.; Pipeleers, D.; In't Veld, P.; De Baetselier P.; et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 2010, 70, 5728-5739.
32. Mulligan, J.K.; Young, M.R. Tumors induce the formation of suppressor endothelial cells in vivo. Cancer Immunol. Immunother. 2010, 59, 267-277.
33. Yoshida, O.; Akbar, S.M.; Chen, S.; Miyake, T.; Abe, M.; Murakami, H.; Hiasa, Y.; Onji, M. Regulatory natural killer cells in murine liver and their immunosuppressive capacity. Liver Int. 2010, 30, 906-912.
34. + cells demonstrating a suppressor T cell-like function in the peripheral blood of colon cancer patients. Int. J. Oncol. 2001, 19, 561-566.
35. Vitale, M.; Rezzani, R.; Rodella, L.; Zauli, G.; Grigolato, P.; Cadei, M.; Hicklin, D.J.; Ferrone, S. HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions. Cancer Res. 1998, 58, 737-742.
36. Vitale, M.; Pelusi, G.; Taroni, B.; Gobbi, G.; Micheloni, C.; Rezzani, R.; Donato, F.; Wang, X.; Ferrone, S. HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage. Clin. Cancer Res. 2005, 11, 67-72.
37. Seliger, B.; Atkins, D.; Bock, M.; Ritz, U.; Ferrone, S.; Huber, C.; Storkel, S. Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing down-regulation. Clin. Cancer Res. 2003, 9, 1721-1727.
38. Dunn, G.P.; Bruce, A.T.; Ikeda, H.; Old, L.J.; Schreiber, R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 2002, 3, 991-998.
39. Sengupta, N.; MacFie, T.S.; MacDonald, T.T.; Pennington, D.; Silver, A.R. Cancer immunoediting and spontaneous tumor regression. Pathol. Res. Pract. 2010, 206, 1-8.
40. Yu, H.; Pardoll, D.; Jove, R. STATs in cancer inflammation and immunity: A leading role for STAT3. Nat. Rev. Cancer 2009, 9, 798-809.
41. Liu, F.S. Mechanisms of chemotherapeutic drug resistance in cancer therapy-A quick review. Taiwan J. Obstet. Gynecol. 2009, 48, 239-244.
42. Bomken, S.; Fiser, K.; Heidenreich, O.; Vormoor, J. Understanding the cancer stem cell. Br. J. Cancer 2010, 103, 439-445.
43. Jain, K.K. Personalized cancer vaccines. Expert Opin. Biol. Ther. 2010, 10, 1637-1647.
44. + T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005, 105, 2862-2868.
45. + suppressor-inducer T-cells. Cancer Res. 1988, 48, 1671-1675.
46. Wada, S.; Yoshimura, K.; Hipkiss, E.L.; Harris, T.J.; Yen, H.R.; Goldberg, M.V.; Grosso, J.F.; Getnet, D.; Demarzo, A.M.; Netto, G.J.; et al. Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. Cancer Res. 2009, 69, 4309-4318.
47. Salem, M.L.; Diaz-Montero, C.M.; Al-Khami, A.A.; El-Naggar, S.A.; Naga, O.; Montero, A.J.; Khafagy, A.; Cole, D.J. Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C). J. Immunol. 2009, 182, 2030-2040.
48. Leao, I.C.; Ganesan, P.; Armstrong, T.D.; Jaffee, E.M. Effective depletion of regulatory T cells allows the recruitment of mesothelin-specific CD8 T cells to the antitumor immune response against a mesothelin-expressing mouse pancreatic adenocarcinoma. Clin. Transl. Sci. 2008, 1, 228-239.
49. + T-cell response to peptide vaccination: Creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. J. Immunother. 2007, 30, 40-53.
50. Schiavoni, G.; Mattei, F.; Di Pucchio, T.; Santini, S.M.; Bracci, L.; Belardelli, F.; Proietti, E. Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: Implications for strategies of chemoimmunotherapy of cancer. Blood 2000, 95, 2024-2030.
51. + regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. 2007, 56, 641-648.
52. Greten, T.F.; Forner, A.; Korangy, F.; N'Kontchou, G.; Barget, N.; Ayuso, C.; Ormandy, L.A.; Manns, M.P.; Beaugrand, M.; Bruix, J. A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. BMC Cancer 2010, 10, 209.
53. + T lymphocytes. Clin. Exp. Immunol. 2007, 150, 523-530.
54. Kong, L.Y.; Wu, A.; Doucette, T.; Wei, J.; Priebe, W.; Fuller, G.N.; Qiao, W.; Sawaya, R.; Rao, G.; Heimberger, A.B. Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immune therapeutic response. Clin. Cancer. Res. 2010, doi: 10.1158/1078-0432.CCR-10-1693.
55. Tongu, M.; Harashima, N.; Yamada, T.; Harada, T.; Harada, M. Immunogenic chemotherapy with cyclophosphamide and doxorubicin against established murine carcinoma. Cancer Immunol. Immunother. 2010, 59, 769-777.
56. Emens, L.A.; Asquith, J.M.; Leatherman, J.M.; Kobrin, B.J.; Petrik, S.; Laiko, M.; Levi, J.; Daphtary, M.M.; Biedrzycki, B.; Wolff, A.C.; et al. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J. Clin. Oncol. 2009, 27, 5911-5918.
57. Gasparini, G. Metronomic scheduling: the future of chemotherapy? Lancet. Oncol. 2001, 2, 733-740.
58. Browder, T.; Butterfield, C.E.; Kraling, B.M.; Shi, B.; Marshall, B.; O'Reilly, M.S.; Folkman, J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drugresistant cancer. Cancer Res. 2000, 60, 1878-1886.
59. Sistigu, A.; Viaud, S.; Chaput, N.; Bracci, L.; Proietti, E.; Zitvogel, L. Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin. Immunopathol. 2011, 33, 369-383.
60. Liu, P.; Jaffar, J.; Hellstrom, I.; Hellstrom, K.E. Administration of cyclophosphamide changes the immune profile of tumor-bearing mice. J. Immunother. 2010, 33, 53-59.
61. + regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels. Cancer Res. 2010, 70, 4850-4858.
62. + myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res. 2005, 11, 6713-6721.
63. Le, H.K.; Graham, L.; Cha, E.; Morales, J.K.; Manjili, M.H.; Bear, H.D. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int. Immunopharmacol. 2009, 9, 900-909.
64. Vincent, J.; Mignot, G.; Chalmin, F.; Ladoire, S.; Bruchard, M.; Chevriaux, A.; Martin, F.; Apetoh, L.; Rebe, C.; Ghiringhelli, F. 5-Fluorouracil selectively kills tumor-associated myeloidderived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010, 70, 3052-3061.
65. Ko, H.J.; Kim, Y.J.; Kim, Y.S.; Chang, W.S.; Ko, S.Y.; Chang, S.Y.; Sakaguchi, S.; Kang, C.Y. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res. 2007, 67, 7477-7486.
66. Rettig, L.; Seidenberg, S.; Parvanova, I.; Samaras, P.; Knuth, A.; Pascolo, S. Gemcitabine depletes regulatory T-cells in human and mice and enhances triggering of vaccine-specific cytotoxic T-cells. Int. J. Cancer 2010, 129, 832-838.
67. Correale, P.; Marra, M.; Remondo, C.; Migali, C.; Misso, G.; Arcuri, F.P.; Del Vecchio, M.T.; Carducci, A.; Loiacono, L.; Tassone, P.; et al. Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC). Eur. J. Cancer 2010, 46, 1703-1711.
68. Correale, P.; Aquino, A.; Giuliani, A.; Pellegrini, M.; Micheli, L.; Cusi, M.G.; Nencini, C.; Petrioli, R.; Prete, S.P.; De Vecchis, L. et al. Treatment of colon and breast carcinoma cells with 5-fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLAA() 02.01 restricted, CEA-peptide-specific cytotoxic T cells in vitro. Int. J. Cancer 2003, 104, 437-445.
69. Correale, P.; Del Vecchio, M.T.; Di Genova, G.; Savellini, G.G.; La Placa, M.; Terrosi, C.; Vestri, M.; Urso, R.; Lemonnier, F.; Aquino, A. et al. 5-fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthase-directed polyepitopic peptide vaccine. J. Natl. Cancer Inst. 2005, 97, 1437-1445.
70. Javeed, A.; Ashraf, M.; Riaz, A.; Ghafoor, A.; Afzal, S.; Mukhtar, M.M. Paclitaxel and immune system. Eur. J. Pharm. Sci. 2009, 38, 283-290.
71. Chen, C.A.; Ho, C.M.; Chang, M.C.; Sun, W.Z.; Chen, Y.L.; Chiang, Y.C.; Syu, M.H.; Hsieh, C.Y.; Cheng, W.F. Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis. Mol. Ther. 2010, 18, 1233-1243.
72. Shurin, G.V.; Tourkova, I.L.; Kaneno, R.; Shurin, M.R. Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12- dependent mechanism. J. Immunol. 2009, 183, 137-144.
73. Pfannenstiel, L.W.; Lam, S.S.; Emens, L.A.; Jaffee, E.M.; Armstrong, T.D. Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice. Cell Immunol. 2010, 263, 79-87.
74. John, J.; Ismail, M.; Riley, C.; Askham, J.; Morgan, R.; Melcher, A.; Pandha, H. Differential effects of Paclitaxel on dendritic cell function. BMC Immunol. 2010, 11, 14.
75. Ramakrishnan, R.; Gabrilovich, D.I. Mechanism of synergistic effect of chemotherapy and immunotherapy of cancer. Cancer Immunol. Immunother. 2011, 60, 419-423.
76. Zhong, H.; Han, B.; Tourkova, I.L.; Lokshin, A.; Rosenbloom, A.; Shurin, M.R.; Shurin, G.V. Low-dose paclitaxel prior to intratumoral dendritic cell vaccine modulates intratumoral cytokine network and lung cancer growth. Clin. Cancer Res. 2007, 13, 5455-5462.
77. Yu, B.; Kusmartsev, S.; Cheng, F.; Paolini, M.; Nefedova, Y.; Sotomayor, E.; Gabrilovich, D. Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer. Clin. Cancer Res. 2003, 9, 285-294.
78. Machiels, J.P.; Reilly, R.T.; Emens, L.A.; Ercolini, A.M.; Lei, R.Y.; Weintraub, D.; Okoye, F.I.; Jaffee, E.M. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res. 2001, 61, 3689-3697.
79. Jiang, H.; Tao, W.; Zhang, M.; Pan, S.; Kanwar, J.R.; Sun, X. Low-dose metronomic paclitaxel chemotherapy suppresses breast tumors and metastases in mice. Cancer Invest. 2010, 28, 74-84.
80. Gadducci, A.; Katsaros, D.; Zola, P.; Scambia, G.; Ballardini, M.; Pasquini, E.; Fertonani, C.; Maggi, L.; Pecorelli, S.; Conte, P.F. Weekly low-dose paclitaxel as maintenance treatment in patients with advanced ovarian cancer who had microscopic residual disease at second-look surgery after 6 cycles of paclitaxel/platinum-based chemotherapy: results of an open noncomparative phase 2 multicenter Italian study (After-6 Protocol 2). Int. J. Gynecol. Cancer 2009, 19, 615-619.
81. Bhatt, R.S.; Merchan, J.; Parker, R.; Wu, H.K.; Zhang, L.; Seery, V.; Heymach, J.V.; Atkins, M.B.; McDermott, D.; Sukhatme, V.P. A phase 2 pilot trial of low-dose, continuous infusion, or metronomic paclitaxel and oral celecoxib in patients with metastatic melanoma. Cancer 2010, 116, 1751-1756.
82. Caballero, M.; Grau, J.J.; Blanch, J.L.; Domingo-Domenech, J.; Auge, J.M.; Jimenez, W.; Bernal- Sprekelsen, M. Serum vascular endothelial growth factor as a predictive factor in metronomic (weekly) Paclitaxel treatment for advanced head and neck cancer. Arch. Otolaryngol. Head Neck. Surg. 2007, 133, 1143-1148.
83. McGuire, W.P., 3rd; Markman, M. Primary ovarian cancer chemotherapy: Current standards of care. Br. J. Cancer 2003, 89 Suppl. 3, S3-S8.
84. Martin, M. Platinum compounds in the treatment of advanced breast cancer. Clin. Breast Cancer 2001, 2, 190-209.
85. du Bois, A.; Herrstedt, J.; Hardy-Bessard, A.C.; Muller, H.H.; Harter, P.; Kristensen, G.; Joly, F.; Huober, J.; Avall-Lundqvist, E.; Weber, B. et al. Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. J. Clin. Oncol. 2010, 28, 4162-4169.
86. Kristensen, G.B.; Vergote, I.; Stuart, G.; Del Campo, J.M.; Kaern, J.; Lopez, A.B.; Eisenhauer, E.; Aavall-Lundquist, E.; Ridderheim, M.; Havsteen, H. et al. First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin. Int. J. Gynecol. Cancer 2003, 13 Suppl. 2, S172-S177.
87. Wu, X.; Feng, Q.M.; Wang, Y.; Shi, J.; Ge, H.L.; Di, W. The immunologic aspects in advanced ovarian cancer patients treated with paclitaxel and carboplatin chemotherapy. Cancer Immunol. Immunother. 2010, 59, 279-291.
88. Huang, X.; Huang, G.; Song, H.; Chen, L. Preconditioning chemotherapy with paclitaxel and cisplatin enhances the antitumor activity of cytokine induced-killer cells in a murine lung carcinoma model. Int. J. Cancer 2011, 129, 648-658.
89. Kyte, J.A.; Gaudernack, G.; Dueland, S.; Trachsel, S.; Julsrud, L.; Aamdal, S. Telomerase Peptide Vaccination Combined with Temozolomide: A Clinical Trial in Stage IV Melanoma Patients. Clin. Cancer Res. 2011, 17, 4568-4580.
90. Slingluff, C.L., Jr.; Petroni, G.R.; Chianese-Bullock, K.A.; Smolkin, M.E.; Ross, M.I.; Haas, N.B.; von Mehren, M.; Grosh, W.W. Randomized Multicenter Trial of the Effects of Melanoma- Associated Helper Peptides and Cyclophosphamide on the Immunogenicity of a Multipeptide Melanoma Vaccine. J. Clin. Oncol. 2011, doi: 10.1200/JCO.2010.33.8053.
91. Neninger, E.; Verdecia, B.G.; Crombet, T.; Viada, C.; Pereda, S.; Leonard, I.; Mazorra, Z.; Fleites, G.; Gonzalez, M.; Wilkinson, B. et al. Combining an EGF-based cancer vaccine with chemotherapy in advanced nonsmall cell lung cancer. J. Immunother. 2009, 32, 92-99.
92. Sampson, J.H.; Aldape, K.D.; Archer, G.E.; Coan, A.; Desjardins, A.; Friedman, A.H.; Friedman, H.S.; Gilbert, M.R.; Herndon, J.E.; McLendon, R.E. et al. Greater chemotherapyinduced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIIIexpressing tumor cells in patients with glioblastoma. Neuro. Oncol. 2010, 13, 324-333.
93. Palermo, B.; Del Bello, D.; Sottini, A.; Serana, F.; Ghidini, C.; Gualtieri, N.; Ferraresi, V.; Catricala, C.; Belardelli, F.; Proietti, E. et al. Dacarbazine treatment before peptide vaccination enlarges T-cell repertoire diversity of melan-a-specific, tumor-reactive CTL in melanoma patients. Cancer Res. 2010, 70, 7084-7092.
94. Yanagimoto, H.; Shiomi, H.; Satoi, S.; Mine, T.; Toyokawa, H.; Yamamoto, T.; Tani, T.; Yamada, A.; Kwon, A.H.; Komatsu, N. et al. A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients. Oncol. Rep. 2010, 24, 795-801.
95. Antonia, S.J.; Mirza, N.; Fricke, I.; Chiappori, A.; Thompson, P.; Williams, N.; Bepler, G.; Simon, G.; Janssen, W.; Lee, J.H. et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin. Cancer Res. 2006, 12, 878-887.
96. Ramlau, R.; Quoix, E.; Rolski, J.; Pless, M.; Lena, H.; Levy, E.; Krzakowski, M.; Hess, D.; Tartour, E.; Chenard, M.P. et al. A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer. J. Thorac. Oncol. 2008, 3, 735-744.
97. Leffers, N.; Vermeij, R.; Hoogeboom, B.N.; Schulze, U.R.; Wolf, R.; Hamming, I.E.; van der Zee, A.G.; Melief, K.J.; van der Burg, S.H.; Daemen, T. et al. Long-term clinical and immunological effects of p53-SLP(R) vaccine in patients with ovarian cancer. Int. J. Cancer 2011, doi: 10.1002/ijc.25980.
98. Kaida, M.; Morita-Hoshi, Y.; Soeda, A.; Wakeda, T.; Yamaki, Y.; Kojima, Y.; Ueno, H.; Kondo, S.; Morizane, C.; Ikeda, M. et al. Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer. J. Immunother. 2011, 34, 92-99.
99. Ohyanagi, F.; Horai, T.; Sekine, I.; Yamamoto, N.; Nakagawa, K.; Nishio, M.; Senger, S.; Morsli, N.; Tamura, T. Safety of BLP25 liposome vaccine (L-BLP25) in Japanese patients with unresectable stage III NSCLC after primary chemoradiotherapy: preliminary results from a Phase I/II study. Jpn. J. Clin. Oncol. 2011, 41, 718-722.
100. Noguchi, M.; Kakuma, T.; Uemura, H.; Nasu, Y.; Kumon, H.; Hirao, Y.; Moriya, F.; Suekane, S.; Matsuoka, K.; Komatsu, N. et al. A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol. Immunother. 2010, 59, 1001-1009.
101. Lesterhuis, W.J.; de Vries, I.J.; Aarntzen, E.A.; de Boer, A.; Scharenborg, N.M.; van de Rakt, M.; van Spronsen, D.J.; Preijers, F.W.; Figdor, C.G.; Adema, G.J. et al. A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients. Br. J. Cancer 2011, 103, 1415-1421.
102. Casares, N.; Pequignot, M.O.; Tesniere, A.; Ghiringhelli, F.; Roux, S.; Chaput, N.; Schmitt, E.; Hamai, A.; Hervas-Stubbs, S.; Obeid, M. et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J. Exp. Med. 2005, 202, 1691-1701.
103. + cytotoxic T lymphocytes. Cancer Immunol. Immunother. 2001, 50, 445-455.
104. Ramakrishnan, R.; Assudani, D.; Nagaraj, S.; Hunter, T.; Cho, H.I.; Antonia, S.; Altiok, S.; Celis, E.; Gabrilovich, D.I. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J. Clin. Invest. 2010, 120, 1111-1124.
105. Andersen, M.H.; thor, S.P. Survivin-A universal tumor antigen. Histol. Histopathol. 2002, 17, 669-675.
106. Altieri, D.C. Survivin and IAP proteins in cell-death mechanisms. Biochem. J. 2010, 430, 199-205.
107. Campoli, M.; Ferris, R.; Ferrone, S.; Wang, X. Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies. Clin. Cancer Res. 2010, 16, 11-20.
108. Rafiq, K.; Bergtold, A.; Clynes, R. Immune complex-mediated antigen presentation induces tumor immunity. J. Clin. Invest. 2002, 110, 71-79.
109. Campoli, M.; Ferrone, S. Immunotherapy of malignant disease: The coming age of therapeutic monoclonal antibodies. In Cancer: Principles & Practive of Oncology; DeVita, V., Hellman, S., Rosenberg, S., Eds; Lippincott Williams and Wilkins: New York, NY, USA, 2009; pp. 1-18.
110. Weiner, L.M.; Surana, R.; Wang, S. Monoclonal antibodies: Versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 2010, 10, 317-327.
111. Gribben, J.G.; Freeman, G.J.; Boussiotis, V.A.; Rennert, P.; Jellis, C.L.; Greenfield, E.; Barber, M.; Restivo, V.A., Jr.; Ke, X.; Gray, G.S. et al. CTLA4 mediates antigen-specific apoptosis of human T cells. Proc. Natl. Acad. Sci. USA 1995, 92, 811-815.
112. Carreno, B.M.; Collins, M. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu. Rev. Immunol. 2002, 20, 29-53.
113. Peggs, K.S.; Quezada, S.A.; Chambers, C.A.; Korman, A.J.; Allison, J.P. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti- CTLA-4 antibodies. J. Exp. Med. 2009, 206, 1717-1725.
114. Maker, A.V.; Attia, P.; Rosenberg, S.A. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J. Immunol. 2005, 175, 7746-7754.
115. Tarhini, A.A.; Iqbal, F. CTLA-4 blockade: Therapeutic potential in cancer treatments. Onco. Targets. Ther. 2010, 3, 15-25.
116. Ribas, A. Clinical Development of the Anti-CTLA-4 Antibody Tremelimumab. Semin. Oncol. 2010, 37, 450-454.
117. Hodi, F.S.; O'Day, S.J.; McDermott, D.F.; Weber, R.W.; Sosman, J.A.; Haanen, J.B.; Gonzalez, R.; Robert, C.; Schadendorf, D.; Hassel, J.C. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363, 711-723.
118. Hwu, P. Treating cancer by targeting the immune system. N. Engl. J. Med. 2010, 363, 779-781.
119. + T cells. Clin. Cancer Res. 2004, 10, 668-680.
120. Baba, T.; Sato-Matsushita, M.; Kanamoto, A.; Itoh, A.; Oyaizu, N.; Inoue, Y.; Kawakami, Y.; Tahara, H. Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A 2402. J. Transl. Med. 2010, 8, 84.
121. Met, O.; Wang, M.; Pedersen, A.E.; Nissen, M.H.; Buus, S.; Claesson, M.H. The effect of a therapeutic dendritic cell-based cancer vaccination depends on the blockage of CTLA-4 signaling. Cancer Lett. 2006, 231, 247-256.
122. Li, N.; Qin, H.; Li, X.; Zhou, C.; Wang, D.; Ma, W.; Lin, C.; Zhang, Y.; Wang, S.; Zhang, S. Synergistic antitumor effect of chemotactic-prostate tumor-associated antigen gene-modified tumor cell vaccine and anti-CTLA-4 mAb in murine tumor model. Immunol. Lett. 2007, 113, 90-98.
123. Chakraborty, M.; Schlom, J.; Hodge, J.W. The combined activation of positive costimulatory signals with modulation of a negative costimulatory signal for the enhancement of vaccinemediated T-cell responses. Cancer Immunol. Immunother. 2007, 56, 1471-1484.
124. Nistico, P.; Capone, I.; Palermo, B.; Del Bello, D.; Ferraresi, V.; Moschella, F.; Arico, E.; Valentini, M.; Bracci, L.; Cognetti, F. et al. Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients. Int. J. Cancer 2009, 124, 130-139.
125. Ohigashi, Y.; Sho, M.; Yamada, Y.; Tsurui, Y.; Hamada, K.; Ikeda, N.; Mizuno, T.; Yoriki, R.; Kashizuka, H.; Yane, K. et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin. Cancer Res. 2005, 11, 2947-2953.
126. Wu, C.; Zhu, Y.; Jiang, J.; Zhao, J.; Zhang, X.G.; Xu, N. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem. 2006, 108, 19-24.
127. Weber, J. Immune Checkpoint Proteins: A New Therapeutic Paradigm for Cancer-Preclinical Background: CTLA-4 and PD-1 Blockade. Semin. Oncol. 2010, 37, 430-439.
128. + lymphocytes in fresh human melanomas enriches for tumorreactive T cells. J. Immunother. 2010, 33, 956-964.
129. + T Cells in Cutaneous T-Cell Lymphoma: Implications for Immune Suppression. Arch. Dermatol. 2010, 146, 1382-1388.
130. Li, B.; VanRoey, M.; Wang, C.; Chen, T.H.; Korman, A.; Jooss, K. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors. Clin. Cancer. Res. 2009, 15, 1623-1634.
131. Mangsbo, S.M.; Sandin, L.C.; Anger, K.; Korman, A.J.; Loskog, A.; Totterman, T.H. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy. J. Immunother. 2010, 33, 225-235.
132. Curran, M.A.; Montalvo, W.; Yagita, H.; Allison, J.P. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl. Acad. Sci. USA 2010, 107, 4275-4280.
133. Brahmer, J.R.; Drake, C.G.; Wollner, I.; Powderly, J.D.; Picus, J.; Sharfman, W.H.; Stankevich, E.; Pons, A.; Salay, T.M.; McMiller, T.L. et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 2010, 28, 3167-3175.
134. Liu, Y.; Yu, Y.; Yang, S.; Zeng, B.; Zhang, Z.; Jiao, G.; Zhang, Y.; Cai, L.; Yang, R. Regulation of arginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-derived suppressor cells. Cancer Immunol. Immunother. 2009, 58, 687-697.
135. Jacobs, J.F.; Punt, C.J.; Lesterhuis, W.J.; Sutmuller, R.P.; Brouwer, H.M.; Scharenborg, N.M.; Klasen, I.S.; Hilbrands, L.B.; Figdor, C.G.; de Vries, I.J.; et al. Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: A phase I/II study in metastatic melanoma patients. Clin Cancer Res. 2010, 16, 5067-5078.
136. Rech, A.J.; Vonderheide, R.H. Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann. N. Y. Acad. Sci. 2009, 1174, 99-106.
137. Ronchetti, S.; Zollo, O.; Bruscoli, S.; Agostini, M.; Bianchini, R.; Nocentini, G.; Ayroldi, E.; Riccardi, C. GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations. Eur. J. Immunol. 2004, 34, 613-622.
138. Coe, D.; Begom, S.; Addey, C.; White, M.; Dyson, J.; Chai, J.G. Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy. Cancer Immunol. Immunother. 2010, 59, 1367-1377.
139. Cohen, A.D.; Schaer, D.A.; Liu, C.; Li, Y.; Hirschhorn-Cymmerman, D.; Kim, S.C.; Diab, A.; Rizzuto, G.; Duan, F.; Perales, M.A. et al. Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS One 2010, 5, e10436.
140. + regulatory T cells. J. Exp. Med. 2005, 202, 885-891.
141. Ramirez-Montagut, T.; Chow, A.; Hirschhorn-Cymerman, D.; Terwey, T.H.; Kochman, A.A.; Lu, S.; Miles, R.C.; Sakaguchi, S.; Houghton, A.N.; van den Brink, M.R. Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity. J. Immunol. 2006, 176, 6434-6442.
142. +) T-cell responses and tumor immunity. Cancer Res. 2006, 66, 4904-4912.
143. Peck, A.; Mellins, E.D. Plasticity of T-cell phenotype and function: The T helper type 17 example. Immunology 2010, 129, 147-153.
144. Mitsui, J.; Nishikawa, H.; Muraoka, D.; Wang, L.; Noguchi, T.; Sato, E.; Kondo, S.; Allison, J.P.; Sakaguchi, S.; Old, L.J. et al. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. Clin. Cancer Res. 2010, 16, 2781-2791.